Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger
09 Fevereiro 2022 - 10:00AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a novel biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders, today announced the appointment of Dr.
Daniel Weinberger to its Scientific Advisory Board (“SAB”).
Dr. Weinberger is the Director and CEO of the
Lieber Institute for Brain Development at the Johns Hopkins Medical
Center and Professor of Psychiatry, Neurology, Neuroscience and
Human Genetics at the Johns Hopkins School of Medicine. He was
formerly Director of the Genes, Cognition, and Psychosis Program of
the Intramural Research Program, National Institute of Mental
Health, National Institutes of Health in Bethesda, Maryland. Dr.
Weinberger attended college at the Johns Hopkins University and
medical school at the University of Pennsylvania and did
residencies in psychiatry at Harvard Medical School and in
neurology at George Washington University. He is board certified in
both psychiatry and neurology.
“We are proud to welcome Dr. Daniel Weinberger
to our Scientific Advisory Board,” said Dr. Tiago Reis Marques, CEO
of Pasithea Therapeutics. “For a generation, Dr. Weinberger has
been at the forefront of the scientific research in
neuropsychiatric disorders. His landmark research in the biological
origins and genetic expressions of schizophrenia has helped
transform the public’s understanding of mental illness. Dr.
Weinberger’s expertise and insight will be critical to Pasithea as
we advance our mission of developing drugs that target the
pathophysiology underlying psychiatric and neurological
disorders.”
“There is no treatment used in psychiatry today
that was discovered based on an understanding of the causative
mechanisms of illness. Pasithea is committed to changing that, to
finding new approaches based on fundamental genetic and molecular
mechanisms of illness. This is music to my ears, and I am thrilled
to be part of the advisory team that will help guide this
pioneering effort to change the landscape of treatment for
neuropsychiatric disorders,” stated Dr. Weinberger.
In 2003, Science magazine highlighted the
genetic research of Dr. Weinberger’s lab as the second biggest
scientific breakthrough of the year, behind the origin of the
cosmos. His recent work has focused on genetic and epigenetic
regulation of the expression in the human brain of genes associated
with developmental brain disorders.
Dr. Weinberger has published over 800 papers in
peer-reviewed journals, and is the recipient of many honors and
awards, including the Sarnat International Prize of the National
Academy of Medicine, The International Neuroscience Prize of the
Gertrud Reemtsma Foundation of the Max Planck Society, the NIH
Directors Award, The Roche-Nature Medicine Neuroscience Award, The
William K. Warren Medical Research Institute Award, the Adolf Meyer
Prize of the American Psychiatric Association, the Foundation's
Fund Prize from the American Psychiatric Association, and the
Lieber Prize of the Brain and Behavior Research Foundation. He is
past president of the Society of Biological Psychiatry and of the
American College of Neuropsychopharmacology, and has been elected
to the National Academy of Medicine of the National Academy of
Sciences.
About Pasithea Therapeutics
Corp.
Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
Contact
Dr. Tiago Reis MarquesChief Executive OfficerE:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024